STUDY OF ACID REFLUX AND ASTHMA (SARA TRIAL)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Asthma and Gastroesophageal Reflux Disease (GERD) are common disorders, usually non-lethal, but with high morbidity and healthcare costs. Asthma occurs in about 4%-7% of the US population, and GERD symptoms occur daily in approximately 7%-20% of US adults. The co-existence of asthma and GERD is far more frequent than chance association. GERD symptoms, although usually mild, occur in up to 65-77% of asthmatics. Often, GERD is "silent" in asthmatics as well, lacking typical symptoms such as heartburn. GERD is particularly frequent in asthmatics with poor asthma control and can induce bronchoconstriction. Poorly controlled asthmatics are often treated for GERD with drugs that suppress gastric acid, but this treatment is expensive and the benefit of such treatment is not established. The objective of this study is to conduct a multi-site randomized clinical trial testing the hypothesis that treatment of GERD with proton-pump inhibitors will reduce the frequency of exacerbations in patients with inadequately controlled asthma.